吴慧茹 卢弘. 托珠单抗治疗幼年特发性关节炎相关葡萄膜炎的研究进展[J]. 中华眼视光学与视觉科学杂志, 2022, 24(2): 150-154.
Huiru Wu, Hong Lu. Progress of Tocilizumab in the Treatment of Juvenile Idiopathic Arthritis Associated Uveitis. Chinese Journal of Optometry Ophthalmology and Visual science, 2022, 24(2): 150-154.
Ravelli A, Consolaro A, Horneff G, et al. Treating juvenile idiopathic arthritis to target: recommendations of an international task force. Ann Rheum Dis, 2018, 77(6): 819-828.DOI: 10.1136/annrheumdis-2018-213030.
[2]
Sen E, Ramanan A. Juvenile idiopathic arthritis-associated uveitis. Clin Immunol, 2020, 211: 108322. DOI: 10.1016/j.clim.
Hawkins MJ, Dick AD, Lee RJ, et al. Managing juvenile idiopathic arthritis-associated uveitis. Surv Ophthalmol, 2016,61(2): 197-210. DOI: 10.1016/j.survophthal.2015.10.005.
[6]
Constantin T, Foeldvari I, Anton J, et al. Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative. Ann Rheum Dis, 2018, 77(8): 1107-1117. DOI: 10.1136/annrheumdis-2018-213131.
Tanaka T, Narazaki M, Kishimoto T. IL-6 in inflammation,immunity, and disease. Cold Spring Harb Perspect Biol, 2014,6(10): a016295. DOI: 10.1101/cshperspect.a016295.
Zahir-Jouzdani F, Atyabi F, Mojtabavi N. Interleukin-6 participation in pathology of ocular diseases. Pathophysiology,2017, 24(3): 123-131. DOI: 10.1016/j.pathophys.2017.05.005.
[14]
Yoshimura T, Sonoda KH, Ohguro N, et al. Involvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitis. Rheumatology (Oxford), 2009, 48(4): 347-354. DOI:10.1093/rheumatology/ken489.
[15]
Wildschütz L, Ackermann D, Witten A, et al. Transcriptomic and proteomic analysis of iris tissue and aqueous humor in juvenile idiopathic arthritis-associated uveitis. J Autoimmun, 2019, 100:75-83. DOI: 10.1016/j.jaut.2019.03. 004.
[16]
Sijssens KM, Rijkers GT, Rothova A, et al. Cytokines,chemokines and soluble adhesion molecules in aqueous humor of children with uveitis. Exp Eye Res, 2007, 85(4): 443-449.DOI: 10.1016/j.exer.2007.06. 011.
[17]
Chen JL, Abiri P, Tsui E. Recent advances in the treatment of juvenile idiopathic arthritis-associated uveitis. Ther Adv Ophthalmol, 2021, 13: 1-14. DOI: 10.1177/ 2515841420984572.
[18]
Kalinina Ayuso V, Makhotkina N, van Tent-Hoeve M, et al.Pathogenesis of juvenile idiopathic arthritis associated uveitis:the known and unknown. Surv Ophthalmol, 2014, 59(5): 517-531. DOI: 10.1016/j.survophthal.2014.03.002.
[19]
Garbers C, Rose-John S. The balance between Treg and TH (17) cells: CD11b and interleukin-6. Eur J Immunol, 2017, 47(4):629-632. DOI: 10.1002/eji.201746988.
[20]
Knochelmann HM, Dwyer CJ, Bailey SR, et al. When worlds collide: Th17 and Treg cells in cancer and autoimmunity. Cell
Tanaka T, Kishimoto T. The biology and medical implications of interleukin-6. Cancer Immunol Res, 2014, 2(4): 288-294.DOI:10.1158/2326-6066.CIR-14-002 2.
[23]
Schett G. Physiological effects of modulating the interleukin-6 axis. Rheumatology (Oxford), 2018, 57(2): 43-50. DOI: 10.1093/rheumato-logy/kex513.
[24]
Scott LJ. Sarilumab: First Global Approval. Drugs, 2017, 77(6):705-712. DOI: 10.1007/s40265-017-0724-2.
[25]
Heissigerová J, Callanan D, de Smet MD, et al. Efficacy and Safety of Sarilumab for the Treatment of Posterior Segment Noninfectious Uveitis (SARIL-NIU): the Phase 2 SATURN Study.Ophthalmology, 2019, 126(3): 428-437. DOI: 10.1016/j.ophtha.2018.09.044.
[26]
Tappeiner C, Heinz C, Ganser G, el al. Is tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis? J Rheumatol, 2012, 39(6):1294-1295. DOI: 10.3899/jrheum.120010.
[27]
Calvo-Río V, Santos-Gómez M, Calvo I, et al. Anti-Interleukin-6 Receptor Tocilizumab for Severe Juvenile Idiopathic Arthritis-
Associated Uveitis Refractory to Anti-Tumor Necrosis Factor Therapy: a Multicenter Study of Twenty-Five Patients. Arthritis
Tappeiner C, Mesquida M, Adán A, et al. Evidence for tocilizumab as a treatment option in refractory uveitis associated with juvenile idiopathic arthritis. J Rheumatol, 2016, 43(12):2183-2188. DOI: 10.3899/ jrheum.160231.
[29]
Maleki A, Manhapra A, Asgari S, et al. Tocilizumab employment in the treatment of resistant juvenile idiopathic arthritis
Alfredo Adán, Moll-Udina A, Alba-Linero D, et al. Recent progress in the treatment of uveitic macular edema. Expert Rev Ophthalmol, 2019, 14(11): 1-10. DOI: 10.1080/17469899.2019.1644168.
[35]
Quesada-Masachs E, Caballero CM. Subcutaneous tocilizumab may be less effective than intravenous tocilizumab in the